NASDAQ$TWST
Twist Bioscience Corporation · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Reported record revenue with a 60% increase year-over-year and increased revenue guidance for full year fiscal 2022.
Twist Bioscience reported record revenue of $56.1 million for the third quarter of fiscal 2022, a 60% increase compared to the same period in fiscal 2021. The company also increased its revenue guidance for the full year fiscal 2022 to $203 million.
- Total orders increased 53% to $59.7 million compared to the third quarter of fiscal 2021.
- Shipped products to approximately 1,900 customers, compared to approximately 1,800 in the third quarter of fiscal 2021.
- Shipped approximately 163,000 genes during the third quarter of fiscal 2022, compared with approximately 107,000 in the third quarter of fiscal 2021.
- Entered into a research, exclusive option and license agreement with Astellas for a Twist-discovered antibody.
Headline financials
Revenue & EPS history
Twist Bioscience · Revenue · Quarterly
$56.1M
Revenue by segment
Twist Bioscience · $177M total across 2 segments · Q3 2022
- NGS Applications$97M—54.8%
- DNA Synthesis & Protein$80M—45.2%
Forward guidance
Twist Bioscience provided updated financial guidance for the full fiscal year 2022, expecting revenue to be approximately $203 million.
Tailwinds
- Revenue is now expected to be approximately $203 million.
- SynBio revenue including Ginkgo Bioworks is expected to be $80 million.
- NGS revenue is estimated to be approximately $97 million.
- Biopharma revenue is estimated to be approximately $26 million.
- Gross margin is expected to be 40% for fiscal 2022
Headwinds
- Operating expenses including R&D and SG&A are expected to be approximately $330 million for the year.
- Net loss is expected to be approximately $250 million, reflecting the impact of the Abveris acquisition in stock-based compensation.
- R&D expense is expected to be approximately $125 million.
- Stock-based compensation is expected to be approximately $80 million.
- Capital expenditures are expected to be in the range of $95 to $100 million, including building out the “Factory of the Future”
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
+0.1%
Avg return
Earnings day
-2.1%
Avg return
5 days after
+0.8%
Avg return
30 days after
47%
14 / 30 earnings
Positive
+29.7%
Q4 2023
Best reaction
-23.2%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | -7.3% | -5.9% | +19.6% | |
| Q1 2026 | +13.8% | -5.9% | -10.2% | |
| Q4 2025 | -10.0% | -14.9% | +3.4% | |
| Q2 2025 | -8.5% | -16.9% | -20.8% | |
| Q1 2025 | +0.7% | -0.1% | -19.7% | |
| Q4 2024 | +12.0% | +14.5% | +20.9% | |
| Q3 2024 | -14.6% | -16.0% | -18.5% | |
| Q2 2024 | +28.9% | +34.9% | +31.1% | |
| Q1 2024 | +9.5% | +5.1% | +16.9% | |
| Q4 2023 | +29.7% | +24.9% | +81.5% | |
| Q3 2023 | +14.9% | +9.3% | +14.0% | |
| Q2 2023 | +3.6% | +2.1% | +26.0% | |
| Q1 2023 | -23.2% | -15.2% | -37.1% | |
| Q4 2022 | +0.8% | +0.5% | -0.6% | |
| Q3 2022 | +20.8% | +12.4% | -17.2% | |
| Q2 2022 | -9.9% | -16.3% | -12.6% | |
| Q1 2022 | -1.0% | +6.0% | -21.0% | |
| Q4 2021 | -12.6% | -14.1% | -22.4% | |
| Q3 2021 | -9.1% | -15.8% | -7.6% | |
| Q2 2021 | +6.2% | -9.4% | -12.4% | |
| Q1 2021 | -16.8% | -5.5% | -38.1% | |
| Q4 2020 | -9.9% | -0.8% | +44.3% | |
| Q3 2020 | -7.2% | -16.3% | -4.8% | |
| Q2 2020 | +5.1% | +4.6% | +0.7% | |
| Q1 2020 | +21.3% | +14.0% | +31.4% | |
| Q4 2019 | +4.6% | +5.8% | -15.5% | |
| Q3 2019 | -11.2% | -11.8% | -13.9% | |
| Q2 2019 | -9.9% | -9.7% | -3.9% | |
| Q1 2019 | -9.2% | -11.8% | -6.9% | |
| Q4 2018 | -9.2% | -9.4% | +18.6% | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro